BB 882

Known as: BB-882 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2005
024619942005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND AND STUDY AIMS Extrahepatic cholestasis is one of the main factors causing liver fibrosis. In this study, we aimed to… (More)
Is this relevant?
2005
2005
The aim of the present study was to investigate the potential effect of treatment with a platelet-activating factor (PAF… (More)
Is this relevant?
2003
2003
Postoperative intra-abdominal adhesion formation is a major clinical problem. We aimed to examine the preventive effect of… (More)
Is this relevant?
2001
2001
BACKGROUND The role of cell adhesion molecules and transmigration of PMNs through the endothelial barrier is probably essential… (More)
Is this relevant?
2000
2000
OBJECTIVE To evaluate the safety and efficacy of the platelet-activating factor receptor antagonist BB-882 in the treatment of… (More)
Is this relevant?
1999
1999
BACKGROUND Endothelial barrier dysfunction is a critical link in the development of tissue injury and organ dysfunction, via… (More)
Is this relevant?
1998
1998
PURPOSE We investigated whether BB-882, a novel potent PAF antagonist, could influence systemic and pulmonary hemodynamics and… (More)
Is this relevant?
1996
1996
Acute pancreatitis is associated with the development of pulmonary dysfunction in a number of patients. The aim of this study was… (More)
Is this relevant?
1996
1996
OBJECTIVE To assess the anti-inflammatory action of lexipafant (BB-882), a platelet activating factor antagonist, in an animal… (More)
Is this relevant?
1996
1996
The effects of bolus doses (0.2-2 micrograms) of platelet-activating factor (PAF) on systemic and pulmonary arterial pressures… (More)
Is this relevant?